Welcome to our dedicated page for Shattuck Labs SEC filings (Ticker: STTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Shattuck Labs, Inc. filings document the regulatory disclosures of a clinical-stage biotechnology company developing DR3-blocking antibodies for inflammatory and immune-mediated diseases. Its 8-K reports cover operating results, financial condition, clinical-program updates for SL-325, material agreements, and capital-structure matters involving its Nasdaq-listed common stock.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, stockholder proposal deadlines, board composition changes, and executive-compensation or equity-award topics. Registration and offering-related disclosures include common stock financing arrangements, Form S-3 materials, and at-the-market offering mechanics.
T. Rowe Price Investment Management, Inc. reports beneficial ownership of 13,432,540 shares of SHATTUCK LABS INC common stock on a Schedule 13G/A (Amendment No. 2). This position represents 15.3% of the outstanding common stock, all with sole dispositive power and 13,391,090 shares with sole voting power.
The firm states that voting and economic benefits ultimately belong to its underlying clients, who may revoke delegated authority. The T. Rowe Price Small-Cap Value Fund is identified as holding 3,565,344 shares, or 5.6% of the class. T. Rowe Price Investment Management expressly denies beneficial ownership in its own right.
Shattuck Labs, Inc. reported second quarter 2026 results and development updates for its DR3-targeted antibody pipeline. The company had $208.3 million in cash, cash equivalents and short-term investments as of June 30, 2026, supported by an $86.2 million underwritten offering and $57.1 million of warrant exercise proceeds, and expects this capital to fund operations into 2029.
For the quarter, Shattuck recorded no revenue, research and development expenses of $11.7 million, general and administrative expenses of $4.5 million, and a net loss of $15.2 million, or $0.12 per share. Phase 1 data for lead antibody SL-325 showed a favorable safety and immunogenicity profile and durable DR3 blockade, with a Phase 2b Crohn’s disease trial expected to start in the third quarter of 2026. Bispecific candidate SL-846 is in IND-enabling GLP toxicology studies, with initial Phase 1 data planned for 2027.
Shattuck Labs, Inc. is a clinical-stage biotechnology company developing DR3-blocking monoclonal and bispecific antibodies for inflammatory and immune‑mediated diseases. The company’s lead program, SL‑325, completed a Phase 1 trial in healthy volunteers, showing a favorable safety profile, dose‑proportional pharmacokinetics, and durable receptor occupancy exceeding 76 days at doses of 1 mg/kg or higher. Management plans to start RECEPTIVE‑CD1, a Phase 2b trial in Crohn’s disease, in the third quarter of 2026, with induction data expected in the first half of 2028. A bispecific candidate, SL‑846, targeting DR3 and IL‑23 receptors, is in non‑human primate toxicology studies, with Phase 1 data planned for 2027.
For the six months ended June 30, 2026, Shattuck reported no revenue and a net loss of $29.9 million compared with $26.2 million a year earlier, driven mainly by higher research and development spending of $22.6 million. General and administrative expenses were $9.1 million. Cash, cash equivalents and short‑term investments totaled $208.3 million, supported by recent equity and warrant financings, and management believes this balance will fund operations for at least twelve months after the financial statements’ issuance date.
Redmile Group, LLC, Jeremy C. Green and Redmile Biopharma Investments II, L.P. updated their ownership report for Shattuck Labs, Inc. common stock. They may be deemed to beneficially own 10,019,421 shares, representing 9.9% of the class, with shared voting and dispositive power over all of these shares. Redmile Biopharma Investments II, L.P. is reported with 8,125,342 shares, or 8.1% of the class.
The position as of July 17, 2026 comprises 5,233,076 shares of common stock (including 3,338,997 shares held directly by RBI II) plus 4,786,345 shares issuable upon exercise of pre-funded warrants, the maximum permitted under a 9.99% Beneficial Ownership Limitation. The Redmile funds hold pre-funded warrants for up to 10,943,951 shares, including 5,647,258 underlying shares at RBI II, and 146,086 shares subject to stock options exercisable within 60 days that are held by a former director as nominee for Redmile. Between July 10 and July 17, 2026, the group executed multiple open market sales and on July 17 used approximately $1,000,000 of working capital to purchase 143,808 shares at a weighted average price of about $7.46 per share.
Shattuck Labs Chief Technical Officer Abhinav A. Shukla reported option exercises and a small share sale in Common Stock. He exercised options to acquire 12,563 shares at $3.57 per share in two transactions and now holds 98,533 Common shares directly.
Shukla also sold 410 shares of Common Stock at a weighted average price of $7.01 per share, with individual sale prices ranging from $7.00 to $7.03. The sale was made under a pre-arranged Rule 10b5-1 trading plan designed to fund option exercise costs and related tax withholding. Following these transactions, he also holds 14,140 stock options with a $3.57 exercise price, expiring on January 25, 2033.
Shattuck Labs Chief Technical Officer Abhinav A. Shukla reported option-related trades in the company’s common stock. On June 30 and July 1, he exercised stock options covering a total of 23,465 shares at an exercise price of $3.57 per share.
The same total of 23,465 shares of common stock was sold in open-market transactions at weighted average prices of about $7.08 and $7.07 per share, under a pre-arranged Rule 10b5-1 trading plan intended to fund the option exercise price and estimated tax withholding. After these transactions, he directly holds 86,380 shares of common stock and continues to hold unexercised portions of an option covering up to 52,200 shares that vests through January 25, 2027.
Shattuck Labs, Inc. Chief Medical Officer Arundathy N. Pandite reported an open-market sale of 30,000 shares of common stock at a weighted average price of $7.01 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 2, 2026.
Following this sale, Pandite continues to hold 136,219 shares of Shattuck Labs common stock directly.
STTK filer reported a proposed sale of 410 shares of Common Stock via a stock option exercise to be sold for cash on 07/02/2026. The filing lists broker Fidelity Brokerage Services LLC.
The filing also discloses recent dispositions in the prior three months: 2,032 shares on 05/12/2026 for $14,235.58, 23,365 shares on 06/30/2026 for $165,468.59, and 100 shares on 07/01/2026 for $707.00.
Abhinav A. Shukla reports a proposed sale of 100 shares of Common Stock via a Form 144 notice dated 07/01/2026. The filing lists the transaction as a stock option exercise with cash used for payment.
The disclosure also shows prior sales during the past three months: 2,032 shares on 05/12/2026 with proceeds $14,235.58, and 23,365 shares on 06/30/2026 with proceeds $165,468.59. The broker/dealer listed is Fidelity Brokerage Services LLC.
STTK filing of a Rule 144 notice records an intended sale of Common stock tied to a Stock Option Exercise with a transaction date of 06/30/2026. The filing lists the broker Fidelity Brokerage Services LLC and shows numeric entries including 23365 and 14235.58 in the disclosure.